iPSC protocol opens the door to explore male infertility treatments
iPSC protocol opens the door to exploring male infertility treatments
Amsbio (Oxford, UK) reports how the Sasaki Lab within the School of Veterinary Medicine at the University of Pennsylvania (PA, US) has devised a protocol in which induced pluripotent stem cells (iPSCs) could be utilized to produce reconstituted human testes.
Since the original publication of their groundbreaking research in 2020, Kotaro Sasaki’s team has made significant progress in reconstituting human testis-like tissue from iPSCs.
A 2025 blog update describes a new protocol for generating xenogeneic reconstituted testes (xrTestes) that support human spermatogonial development in vitro. These findings strengthen the potential of the Sasaki Lab system as a valuable model for studying early human spermatogenesis and offer a practical and scalable platform for further research in reproductive biology. The strides made by researchers in the Sasaki Lab are paving a new way for studies to explore treatments for male infertility.
To support reproductive biology research, Amsbio offers a wide range of reagents for stem-cell culture, differentiation, and 3D tissue modeling.
The Sasaki Lab chose to use StemFit® feeder-free, chemically defined stem cell culture media from Amsbio to maintain their iPSC culture. In addition, the xrTestes cells were cultured on plates coated in recombinant laminin E8 fragments using iMatrix-511 silk from Amsbio. The Sasaki lab also cryopreserved their cells using CELLBANKER 1 from Amsbio, a trusted solution for the storage of any cell type including sensitive cell lines. CELLOTION™ cell wash and recovery solution from Amsbio was also used by the lab to collect FACS-sorted in vitro cells prior to single-cell RNA-seq library preparation.
To learn more about the Sasaki Lab’s latest advances in developing reconstituted human testes cells from iPSCs read the full 2025 blog update at https://www.amsbio.com/news/reconstituting-human-testes-from-ipscs.
For further information on Stem Cell Synergy Solutions from Amsbio please visit https://www.amsbio.com/research-areas/stem-cells or contact the company on +31-72-8080244 / +44-1235-828200 – +1-617-945-5033 / [email protected]
About Amsbio
Now part of the Europa Biosite group of companies, AMS Biotechnology (Amsbio) is recognized as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for R&D in the medical, nutrition, cosmetics and energy industries. Amsbio has in-depth expertise in extracellular matrices (ECMs) to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows Amsbio to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, Amsbio offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, Amsbio is widely recognized as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cells and cell therapy applications. This includes GMP cryopreservation technology and high-quality solutions for viral delivery.
